Dr. Baker keynote speaker for NAMI statewide meetings in Wisconsin and Montana
April 12, 2011
Dr. Baker will be the keynote speaker at the annual conferences for the Wisconsin and Montana state chapters of the National Alliance on Mental Illness (NAMI). The Wisconsin Chapter will hold their meeting April 15-16 at the Hilton Milwaukee City Center. The Montana Chapter will hold their meeting November 2-4 at the Heritage Inn in Great Falls. In both presentations, Dr. Baker will discuss how attempts to develop drugs that target the pathophysiology of the glutamate system in schizophrenia may lead to a new, more effective class of antipsychotics.
Click here to visit the NAMI Wisconsin website.
Click here to visit the NAMI Montana website.
Dr. Baker presents findings in New York
March 9, 2011
The New York Academy of Sciences sponsored a conference, Advancing Drug Discovery for Schizophrenia, to bring scientists and clinicians together to present innovative pharmacological agents for the treatment of schizophrenia. Dr. Baker presented findings at this conference suggesting the antipsychotic potential of agents that target a novel mechanism within the glutamate system.
Click here to visit the New York Academy of Sciences website.
Promentis awarded over $244,000 in Qualifying Therapeutic Discovery Program
November 2, 2010
The Qualifying Therapeutic Discovery Project grant is provided to projects that show a reasonable potential to result in new therapeutics to treat areas of unmet medical need and to reduce the long-term health care costs in the United States. Based on an application submitted earlier in 2010, Promentis received an award of $244,479 corresponding to qualified investment in 2009 and 2010.
Click here to visit the
Qualifying Therapeutic Discovery Program website.
Creating New Drugs, Creating New Biotech Companies
Hosted by Stephanie Lecci of WUWM's Lake Effect
Posted: Jun 17, 2010
Four Marquette University professors start their own biotech companies to develop new and better drugs to treat schizophrenia. John Mantsch is an associate professor and chair in biomedical sciences. Dave Baker is associate professor of biomedical sciences. They launched Promentis Pharmaceuticals. Baker was recently named one of the Business Journal of Milwaukee’s Forty Under 40, and Mantsch was awarded a grant renewal by the NIH for his research on cocaine addiction. Click here to listen to the radio broadcast.
Click here to visit the WUWM: Lake Effect website.
Dr. Baker is the recipient of the 2010 Daniel X. Freedman Award
Posted: Jun 16, 2010
The Freedman Award for Outstanding Basic Research is an honorary distinction for outstanding basic research established in 1998 to honor the late Daniel X. Freedman, M.D., a pioneer in biological psychiatry. The Freedman Award Committee is comprised of NARSAD Scientific Council members with expertise in basic research.
Click here to visit the NARSAD website.
Biomedical sciences professor receives $1.5 million grant
Marquette University News Center
Posted: Jun 15, 2010
Dr. John Mantsch, associate professor and chair of biomedical sciences in Marquette University’s College of Health Sciences, has been awarded a five-year, $1.5 million grant renewal from the National Institutes of Health for his research on cocaine addiction. The grant provides critical support of a research project Mantsch started in 2002, which examines the neuropathways through which susceptibility to drug relapse during periods of stress is heightened in cocaine addiction.
Click here to read the full story on the Marquette University Marketing & Communication website.
Promentis Pharmaceuticals Raises $1.94 Million
By Kathleen Gallagher of the Journal Sentinel
Posted: Feb. 25, 2010
A Milwaukee company that's developing drugs to treat schizophrenia and other central nervous system disorders said Thursday it has raised $1.94 million from investors. Promentis Pharmaceuticals Inc. will use the money to further develop compounds to use for treatments, said Daniel Lawton, Promentis' president and chief executive.
Click here to read the full story on the JSOnline website.
Dr. David Baker Named to Business Journal "Forty Under 40" winners
The Business Journal of Milwaukee
February 19, 2010
“This is a great group of honorees,” said Mark Kass, editor of The Business Journal. “They represent the best and the brightest of the future community leaders of southeast Wisconsin.” The Business Journal received about 250 nominations for this year’s program. The winners range from attorneys to retail store owners to real estate executives. The winners were honored in a special section in the April 9 issue of The Business Journal and at an April 12 awards event at The Pfister Hotel.
Click here to read the full article on the Business Journal website.
Governor Doyle Announces Funding for Promentis Pharmaceuticals, Inc.
"February 10, 2010
Promentis Pharmaceuticals, Inc. is exactly the type of company our state should be investing in - companies that are developing innovative solutions in the biotechnology industry. I am pleased we can assist this company in its growth and development."
-Wisconsin Governor Jim Doyle
Click here to read the full press release on the Wisconsin Department of Commerce website.
Small Drug Firms Thriving in Area
Companies rely on innovation in industry
By Kathleen Gallagher of the Journal Sentinel
Posted: Feb. 28, 2009
As Schwarz Pharma Inc. grew, Daniel Lawton envisioned a day when the company might be sold and he'd have to leave Milwaukee. That day came in late 2006, and to Lawton's surprise, he didn't go anywhere. Instead, he and two partners who had helped build a formidable drug pipeline from Schwarz Pharma's U.S. headquarters in Mequon launched Promentis Pharmaceuticals Inc., a company that's developing drugs for schizophrenia and other central nervous system disorders from its offices in downtown Milwaukee.
Click here to read the full story on the JSOnline website.
Searching for a Cure for the Brain's Darkest Diseases
By Nicole Sweeney Etter | Marquette Magazine
Winter 2009
Day after day, Dr. David Baker hunched over his lab bench searching for a sign that he was on the right track. As a post-doctoral fellow, he was engaged in a risky project: deviating from the neuroscience establishment by studying the role of glutamate in addiction, while virtually everyone else focused on another neurotransmitter called dopamine. It was slow, painstaking work. But it was then that Baker made the most remarkable discovery of his young career, one that propelled him to where he is today. Now an assistant professor of biomedical sciences in Marquette’s College of Health Sciences, Baker and Marquette colleague Dr. John Mantsch have started their own company, Promentis Pharmaceuticals, that could deliver promising new treatments for schizophrenia and other neurological disorders.
Click here to read the full article on the Marquette Magazine website.
